Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro

Crit Care Med. 2003 Apr;31(4):1147-53. doi: 10.1097/01.CCM.0000060005.48885.2B.

Abstract

Objective: Gabexate mesilate, a synthetic protease inhibitor, has been shown to reduce endotoxin-induced pulmonary vascular injury in an animal model of sepsis by inhibiting leukocyte activation. We examined whether gabexate mesilate inhibits tumor necrosis factor-alpha-induced expression of leukocyte adhesion molecules in cultured endothelial cells.

Design: Prospective, randomized, controlled study.

Setting: Research laboratory at a university medical center.

Subjects: Cultured human umbilical vein endothelial cell (HUVECs).

Interventions: HUVECs were stimulated with tumor necrosis factor-alpha or lipopolysaccharide in the presence or absence of gabexate mesilate. Expression of E-selectin and intercellular adhesion molecule-1 was measured by cellular enzyme-linked immunosorbent assay. Messenger RNA levels of E-selectin and intercellular adhesion molecule-1 were determined by reverse transcription-polymerase chain reaction. DNA-binding activity of p65 in the nuclear extracts was evaluated by enzyme-linked immunosorbent assay. Nuclear translocation of nuclear factor-kappaB induced by tumor necrosis factor-alpha was evaluated by immunocytostaining and Western blot analysis. Degradation and phosphorylation of inhibitor of nuclear factor-kappaB (IkappaB) induced by tumor necrosis factor-alpha were evaluated by Western blot analysis.

Measurements and main results: Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced increases in the endothelial expression of E-selectin and intercellular adhesion molecule-1 by inhibiting the transcription. Tumor necrosis factor-alpha-induced increase in DNA binding of p65 was inhibited by gabexate mesilate through inhibition of the nuclear translocation of p65. Gabexate mesilate inhibited the tumor necrosis factor-alpha-induced degradation of IkappaBalpha, an inhibitor of nuclear factor-kappaB, by inhibiting phosphorylation of IkappaBalpha in HUVECs.

Conclusions: Gabexate mesilate inhibited the expression of leukocyte adhesion molecules by inhibiting the nuclear factor-kappaB-mediated transcription in HUVECs. Inhibition of nuclear factor-kappaB activation by gabexate mesilate could be explained by inhibition of degradation of IkappaB. Gabexate mesilate might reduce lipopolysaccharide-induced pulmonary vascular injury not only by inhibiting monocytic tumor necrosis factor-alpha production but by inhibiting the expression of endothelial leukocyte adhesion molecules.

MeSH terms

  • Anticoagulants / pharmacology*
  • Blotting, Western
  • Cell Adhesion Molecules / metabolism*
  • Cells, Cultured
  • E-Selectin / metabolism
  • Endothelium, Vascular / metabolism*
  • Enzyme-Linked Immunosorbent Assay
  • Gabexate / pharmacology*
  • Humans
  • I-kappa B Proteins / metabolism
  • Immunohistochemistry
  • In Vitro Techniques
  • Intercellular Adhesion Molecule-1 / metabolism
  • Lipopolysaccharides / pharmacology
  • NF-kappa B / metabolism
  • RNA, Messenger / analysis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Serine Proteinase Inhibitors / pharmacology*
  • Transcriptional Activation / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology
  • Umbilical Veins

Substances

  • Anticoagulants
  • Cell Adhesion Molecules
  • E-Selectin
  • I-kappa B Proteins
  • Lipopolysaccharides
  • NF-kappa B
  • RNA, Messenger
  • Serine Proteinase Inhibitors
  • Tumor Necrosis Factor-alpha
  • Intercellular Adhesion Molecule-1
  • Gabexate